| The GEMI Fund is a research fund founded by Linde Gas Therapeutics in co-operation with Harvard Medical International in Boston, Mass. USA and the Karolinska Institute in Stockholm, Sweden in order to support gas enabled medical innovations – GEMI.
Harvard Medical International and the Karolinska Institute are scientific partners and members of the The GEMI Fund board together with representatives appointed by Linde Gas Therapeutics.
Linde Gas Therapeutics provides the funding.
Harvard Medical International(HMI) is a self-supporting not-for-profit subsidiary of Harvard Medical School whose role is to extend internationally the School's tradition of improving the quality of health care through excellence in clinical medicine, medical education, and biomedical research. Since its inception in 1994, HMI has created numerous partnerships with academic institutions, health care providers, governments and non-governmental organizations, and other organizations around the world. The guiding philosophy of HMI is that every citizen of the world should have access to quality health care of a world standard.
The Karolinska Institutet(KI) is one of Europe’s largest medical universities. It is also Sweden’s largest center for medical training and research accounting for 30 per cent of the medical training and 40 per cent of the medical academic research that is conducted nationwide. KI's mission is to improve the health of mankind through research, education and information. KI handles the awarding of the Nobel Prize in Physiology or Medicine since 1895, when appointed by Alfred Nobel, with the first prize awarded in 1901.
Linde Gas Therapeutics is a leading provider of pharmaceutical gases worldwide. In this fast-emerging market, Linde Gas Therapeutics is positioning itself as the preferred partner in the development of proprietary therapies and diagnostic procedures, where gases, gas technology or gas competence is needed. For example, Linde Gas Therapeutics was extensively involved in the development of nitric oxide into a pharmaceutical product INOmax®. This product is used for the treatment of certain term and near-term neonates with hypoxic respiratory failure.
Linde Gas Therapeutics enjoys close co-operation with hospitals and universities in Europe and the US supporting research programs in the area of pharmaceutical gases.
® INOmax is a registered trademark of AGA AB.
|
